Table 1.
Summary basic characteristics of included studies.
| Study | Year of publication | Sample size | Mean age (SD) | Gender (M/F) | Type of cardiac surgery | Type 1 of priming fluid | Type 2 of priming fluid | Type 3 of priming fluid | Volume of priming fluid |
|---|---|---|---|---|---|---|---|---|---|
| Barbu | 2020 | 39/41 | 65.8(6.1)/67.0(7.6) | 28/11;29/12 | Elective cardiac surgery | Dextran-based solution | Ringer acetate | NR | 1300 ml |
| Choi | 2010 | 18/18 | 54(12)/55(14) | 5/13;6/12 | Elective mitral valvular heart surgery | 6% HES 130/0.4 | 5% HA | NR | 500 ml |
| Gurbuz | 2013 | 100/100 | 61.52(9.29)/61.81(10.12) | 74/26;77/23 | CABG surgery | 6% HES 130/0.4 | Balanced multielectrolyte solution | NR | NR |
| Kamra | 2013 | 10/10 | 55(18.8)/59(7.1) | 9/1;9/1 | CABG surgery | Plasmalytes | 5% HA | NR | NR |
| Kolsrud | 2022 | 39/41 | 65.8(6.1)/67.7(7.6) | 28/11;29/12 | Elective cardiac surgery | Dextran 40 | Ringer-acetate plus mannitol | NR | 1300 ml |
| Kuitunen | 2004 | 15/15/15 | 57/60/58 | 13/2;14/1;15/0 | Elective CABG surgery | 4% HA | 6% HES 120 | 6% HES 400 | 20 ml/kg |
| Kuitunen | 1993 | 15/15/15 | 57(2)/57(2)/57(2) | 12/3;12/3;12/3 | Elective primary CABG | Low molecular weight-HES | High molecular weight-HES | Ringer’s solution | 2000 ml |
| Linden | 2004 | 55/55 | 63(8)/63(11) | 35/20;37/18 | Elective coronary artery or single valve surgery | 6% HES 200/0.5 | 3.5% UREA-linked gelatin | NR | 30 ± 3 ml/kg/day |
| Liou | 2012 | 10/10/10 | 69.8(2.7)/62.4(2.9)/64.1(4.3) | 7/3;8/2;9/1 | Elective CABG surgery | 10% HES 200/0.5 | Ringer’s solution | 25% HA | 950 ml |
| Lou | 2012 | 35/35 | 49.9(13.2)/51.5(13.7) | 23/12;19/16 | Elective first-time cardiac surgery | 6% HES 130/0.4 | 4% Gelatin | NR | NR |
| Maleki | 2016 | 30/30 | 61.85(9.10)/66.07(8.82) | 17/13;21/9 | Cardiopul monary CABG surgery | 6% HES 130/0.4 | 5% HA | NR | NR |
| Min | 2013 | 45/45 | 56.4(10.7)/59.7(9.0) | 39/6;36/9 | Elective CABG surgery | 6% HES 130/0.4 | 4% succinylated gelatin | NR | HES: 1,942.3 ± 1,046.1 ml, Gelatin: 1973.3 ± 728.8 ml |
| Moerman | 2016 | 20/20 | 65(9)/68(10) | 15/5;18/2 | Elective CABG surgery | 6% HES 130/0.4 | Modified fluid gelatin | NR | NR |
| Schramko | 2015 | 19/16 | 73.6(7.8)/73.6(6.4) | 13/6;8/7 | CABG or Valve procedure | 6% HES 130/0.42 | Ringer’s acetate solution | NR | 2000 ml |
| Schweizer | 2019 | 15/15 | >18 | / | Elective conventional adult cardiac surgery | 6% HES 130/0.4 | Sodium chloride (NaCl) 0.9% | NR | 1000 mL |
| Shahbazi | 2010 | 35/35 | 57.4(9.3)/57.6(9.0) | 26/9;21/14 | Elective CABG surgery | HES 130/0.4 | Ringer’s lactate | NR | NR |
| Svendsen | 2018 | 20/18 | 67(10)/62(10) | 17/3;18/0 | Elective CABG surgery | 6% HES 130/0.42 | Ringer’s solution | NR | 1700 ml |
| Tamayo | 2008 | 22/22 | 67.8(8.1)/66.50(6.9) | 19/3;17/5 | Elective CABG surgery | Gelatin-containing solution | Ringer’s lactate | NR | NR |
| Tiryakioğlu | 2008 | 70/70 | 56(8)/58(7) | 60/10;60/10 | CABG surgery | HES 130/0.4 | Ringer solution | NR | 1500 ml |
| Vanhoonacker | 2009 | 82/72 | 67.31(9.30)/66.34(9.51) | 66/16;56/16 | CABG surgery | 6% HES 130/0.4 | Modified fluid gelatin | NR | 1500 ml |
| Yap | 2007 | 20/20 | 59/63 | 17/3;17/3 | CABG surgery | HES 130/0.4 | Gelofusine | NR | NR |
HA: Human albumin; HES: Hydroxyethyl starch; CABG: Coronary artery bypass graft; NR: Not reported.